参考文献/References:
[1] Ahadi F,Azadi M,Biglari M,et al. Evaluation of coronary stents:a review of types,materials,processing techniques,design,and problems[J]. Heliyon,2023,9(2):e13575.[2] Otto S,Díaz VAJ,Weilenmann D,et al. Crystalline sirolimus-coated balloon (cSCB) angioplasty in an all-comers,patient population with stable and unstable coronary artery disease including chronic total occlusions:rationale,methodology and design of the SCORE trial[J]. BMC Cardiovasc Disord,2023,23(1):176.[3] Butala NM,Yeh RW. Improvements in coronary stent design?ranslate to better real-world outcomes[J]. JACC Asia,2021,1(3):357-359.[4] Park D,Jeong M,Jin Y,et al. Preclinical evaluation of an everolimus-eluting bioresorbable vascular scaffold via a long-term rabbit iliac artery model[J]. Tissue Eng Regener Med,2023,20(2):239-249.5] Vidovich M. Three Decades of SVG PCI:A Short History of Nearly Everything[J]. JACC Case Rep,2023,10:101744.[6] Bedair T,Cho Y,Joung Y,et al. Biodegradable polymer brush as nanocoupled interface for improving the durability of polymer coating on metal surface[J]. Colloids Surf,B,2014,122:808-817.[7] Zhang Y,Wu Z,Wang S,et al. Clinical outcome of paclitaxel-coated balloon angioplasty versus drug-eluting stent implantation for the treatment of coronary drug-eluting stent in-stent chronic total occlusion[J]. Cardiovasc Drugs Ther,2022,7:363-367.[8] Kawagoe Y,Otsuka F,Onozuka D,et al. Early vascular responses to abluminal biodegradable polymer-coated versus circumferential durable polymer-coated newer-generation drug-eluting stents in humans:a pathological study[J]. EuroIntervention,2023,18(15):1284-1294.[9] Bedair T,Elnaggar M,Joung Y,et al. Recent advances to accelerate re-endothelialization for vascular stents[J]. J Tissue Eng,2017,8:2041731417731546.[10] Kawarada O,Otsuka F,Miki K,et al. Heterogeneous vascular response after implantation of bare nitinol self-expanding stents in the swine femoropopliteal artery[J]. Cardiovasc Intervention Ther,2023,38(2):210-222.[11] Zhu Y,Liang L,Parasa R,et al. Early vascular healing after neXt-generation drug-eluting stent implantation in Patients with non-ST Elevation acute Coronary syndrome based on optical coherence Tomography guidance and evaluation (EXPECT):study protocol for a randomized controlled trial[J]. Front Cardiovasc Med,2023,10:1003546.[12] Chang S,Hla T. Post-transcriptional gene regulation by HuR and microRNAs in angiogenesis[J]. Curr Opin Hematol,2014,21(3):235-240.[13] Uren P,Burns S,Ruan J,et al. Genomic analyses of the RNA-binding protein Hu antigen R (HuR) identify a complex network of target genes and novel characteristics of its binding sites[J]. Biol Chem,2011,286(43):37063-37066.[14] Zhu K,Gao T,Wang Z,et al. RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation[J]. Cell death discovery,2023,9(1):151.[15] Zheng X,Li S,Yu J,et al. N6-methyladenosine reader IGF2BP3 as a prognostic Biomarker contribute to malignant progression of glioma[J]. Transl Cancer Res,2023,12(4):992-1005.[16] He J,Ma X. Interaction between LncRNA and UPF1 in tumors[J]. Front Genet,2021,12(62):490-495.[17] Palo A,Patel S,Sahoo B,et al. FRG1 is a direct transcriptional regulator of nonsense-mediated mRNA decay genes[J]. Genomics,2023,115(1):110539.[18] Banerjee R,van Tubergen EA,Scanlon CS,et al. The G protein-coupled receptor GALR2 promotes angiogenesis in head and neck cancer[J]. Mol Cancer Ther,2014,13(5):1323-1333.[19] Zhang D, Zhou Z, Yang R, et al. Tristetraprolin, a Potential Safeguard Against Carcinoma: Role in the Tumor Microenvironment[J]. Frontiers in Oncology, 2021, 11: 632189.[20] Merkulova T, Broqueres D,Kubis N,et al. Towards the therapeutic use of vascular smooth muscle progenitor cells[J]. Cardiovasc Res,2012,95(2):205-214.[21] Liu Z,Zhang G,Chen J,et al. G-CSF promotes the viability and angiogenesis of injured liver via direct effects on the liver cells[J]. Mol Biol Rep,2022,49(9):8715-8725.[22] Ziauddin S,Nakashima M,Watanabe H,et al. Biological characteristics and pulp regeneration potential of stem cells from canine deciduous teeth compared with those of permanent teeth[J]. Stem Cell Res Ther,2022,13(1):439.[23] Aggarwal V,Tuli H,Varol A,et al. Role of reactive oxygen species in cancer progression:molecular mechanisms and recent advancements[J]. Biomolecules,2019,9(11):735.[24] Yoshida T, Yamashita M, Horimai C, et al. Smooth Muscle–Selective Inhibition of Nuclear Factor‐κB Attenuates Smooth Muscle Phenotypic Switching and Neointima Formation Following Vascular Injury[J]. Journal of the American Heart Association Cardiovascular & Cerebrovascular Disease, 2013, 2(3):e000230.[25] Rohani M, Parks W. Matrix remodeling by MMPs during wound repair[J]. Matrix Biol,2015,44-46:113-121.[26] Quintero S,Arreola R,Becerril E,et al. Role of matrix metalloproteinases in angiogenesis and cancer[J]. Front Oncol,2019,9(1):1370.[27] Scheau C,Badaraui A,Costache R,et al. The role of matrix metalloproteinases in the epithelial-mesenchymal transition of hepatocellular carcinoma[J]. Anal Cell Pathol,2019,11:9423907.[28] Kessler T,Zhang L,Liu Z,et al. ADAMTS-7 inhibits re-endothelialization of injured arteries and promotes vascular remodeling through cleavage of thrombospondin-1[J]. Circulation,2015,131(13):1191.[29] Gligorijevic N,?kalovic V,Penezic A,et al. Characterisation of the binding of dihydro-alpha-lipoic acid to fibrinogen and the effects on fibrinogen oxidation and fibrin formation[J]. Int J Biol Macromol,2020,147:319-325.[30] Longhi G,Ghidinelli S,Abbate S,et al. Insights into the structures of bilirubin and biliverdin from vibrational and electronic circular dichroism:history and perspectives[J]. Molecules,2023,28(6):2564.[31] Gligorijevic N,Minic S,Robajac D,et al. Characterisation and the effects of bilirubin binding to human fibrinogen[J]. Int J Biol Macromol,2019,128:74-79.[32] Buddhadasa M,Lerouge S,Girard P. Plasma polymer films to regulate fibrinogen adsorption:Effect of pressure and competition with human serum albumin[J]. Plasma Processes Polym,2018,15(9):e1800040.[33] Ariyaratne T,Ademi Z,Huq M,et al. The real-world cost-effectiveness of coronary artery bypass surgery versus stenting in high-risk patients:propensity score-matched analysis of a single-centre experience[J]. Applied health economics and health policy,2018,16(5):661-674.[34] Lee P,Brennan A,Stub D,et al. Estimating the economic impacts of percutaneous coronary intervention in Australia:a registry-based cost burden study[J]. BMJ open,2021,11(12):e053305.[35] Rykowska I,Nowak I,Nowak R. Drug-eluting stents and balloons—Materials,structure designs,and coating techniques:a review[J]. Molecules,2020,25(20):4624.[36] Jensen L,Christiansen E. Are drug-eluting stents safer than bare-metal stents[J]. Lancet,2019,393(10190):2472-2474.[37] Piccolo R,Bonaa K H,Efthimiou O,et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention:a systematic review and individual patient data meta-analysis of randomised clinical trials[J]. Lancet,2019,393(10190):2503-2510.[38] Yamamoto K,Sato T,Salem H,et al. Mechanisms and treatment outcomes of ostial right coronary artery in-stent restenosis[J]. EuroIntervention,2023,19(5):e383-e393.[39] Kim B,Moon H,Kim S,et al. Outcomes of percutaneous coronary intervention in elderly patients with rheumatoid arthritis:a nationwide population-based cohort study[J]. Healthcare,2023,11(10):1381.[40] Gherasie F,Valentin C,Busnatu S. Is there an advantage of ultrathin-strut drug-eluting stents over second- and third-generation drug-eluting stents[J]. J Pers Med,2023,13(5):753.[41] Rigatelli G,Zuin M,Vassilev D,et al. Risk of dislodgement of ultrathin drug eluting stents versus thick drug eluting stents[J]. Am J Cardiol,2020,125(11):1619-1623.[42] Wang G,Zhao Q,Chen Q,et al. Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis[J]. Coron Artery Dis,2019,30(7):473-480.[43] Kaul U,Bhatia V. The trade-off of a long drug-eluting stent[J]. EuroIntervention,2021,16(16):1297-1298.[44] Zhang B,Qin Y,Wang Y. A nitric oxide-eluting and REDV peptide-conjugated coating promotes vascular healing[J]. Biomaterials,2022,284:121478.[45] Binder R,Lüscher T. Duration of dual antiplatelet therapy after coronary artery stenting:where is the sweet spot between ischaemia and bleeding[J]. Eur Heart J,2015,36(20):1207-1211.[46] Yang L,Li L,Wu H,et al. Catechol-mediated and copper-incorporated multilayer coating:An endothelium-mimetic approach for blood-contacting devices[J]. J Controlled Release,2020,321:59-70.[47] Kr?er N,Kopp A,Staudt M,et al. Hemocompatibility of plasma electrolytic oxidation (PEO) coated Mg-RE and Mg-Zn-Ca alloys for vascular scaffold applications[J]. Mater Sci Eng,2018,92:819-826.[48] Hong Q,Zhou H,Cheng Y,et al. Synthesis of star 6-arm polyethylene glycol-heparin copolymer to construct anticorrosive and biocompatible coating on magnesium alloy surface[J]. Front Bioeng Biotechnol,2022,10:853487.[49] Liu Y,Zhang J,Wang J,et al. Tailoring of the dopamine coated surface with VEGF loaded heparin/poly-L-lysine particles for anticoagulation and accelerate in situ endothelialization[J]. J Biomed Mater Res A,2015,103(6):2024-2034.
相似文献/References:
[1]韩培天 魏晓岩 杜彬彬 张津宁 王文州 郭艳娇 张克成 李春彦 李文慧.心肌缺血时间对STEMI患者急诊PCI术后早期左室舒张功能的影响及相关因素分析[J].心血管病学进展,2020,(6):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
HAN Pei-tian,WEI Xiaoyan,DU Binbin,et al.Effect of Myocardial Ischemia Duration on Early Left Ventricular Diastolic Function in STEMI Patients After Emergency PCI and Analysis of Related Factors[J].Advances in Cardiovascular Diseases,2020,(3):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
[2]贺彩红 荣晶晶 潘宏伟.定量血流分数在急性心肌梗死中的应用进展[J].心血管病学进展,2021,(4):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
HE Caihong,RONG Jingjing,PAN Hongwei.Progress in the Application of Quantitative Flow Ratio in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(3):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
[3]陈佳仑 李树仁.不同策略血栓抽吸对于急性ST段抬高心肌梗死患者的研究进展[J].心血管病学进展,2021,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
CHEN Jialun,LI Shuren.Different Strategies of Thrombus Aspiration in Patients with Acute ST Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(3):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
[4]梁晨笛 秦纲.经皮冠状动脉介入诊疗中穿刺路径研究进展[J].心血管病学进展,2022,(3):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
LIANG Chendi,QIN Gang.Puncture Routes in Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(3):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[5]马兴鸿 汪蕾 方纬.核素心肌显像在冠状动脉慢性完全闭塞临床诊疗中的应用价值[J].心血管病学进展,2022,(4):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
MA Xinghong,WANG Lei,FANG Wei.Application Value of Radionuclide Myocardial Imaging In the Clinical Diagnosis And Treatment of Coronary Chronic Total Occlusion[J].Advances in Cardiovascular Diseases,2022,(3):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
[6]张爽 吴娜琼.腔内影像学在冠状动脉支架内再狭窄诊治应用中的研究进展[J].心血管病学进展,2022,(5):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
ZHANG Shuang,WU Na qiong.Application of Intravascular Imaging in Diagnosis and Treatment of Coronary In-Stent Restenosis[J].Advances in Cardiovascular Diseases,2022,(3):389.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.002]
[7]管翔 王宇 张成糕 周健 张艺 李庆国.经皮心室辅助装置在复杂高危冠状动脉介入治疗中的应用进展[J].心血管病学进展,2022,(5):394.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.003]
GUAN Xiang,WANG Yu,ZHANG Chenggao,et al.Application Progress of Percutaneous Ventricular Assist Device in Complex High-Risk Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(3):394.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.003]
[8]刘文 魏芳晶.药物涂层球囊在真性分叉病变中的研究进展[J].心血管病学进展,2022,(6):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
LIU WenWEI Fangjing.Study of Drug-Coated?Balloon in?rue Coronary Bifurcation Lesions[J].Advances in Cardiovascular Diseases,2022,(3):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
[9]宋艳华 来春林 杨五小.急性 ST段抬高型心肌梗死患者微血管功能障碍的研究进展[J].心血管病学进展,2022,(6):530.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.013]
SONG Yanhua,LAI Chunlin,YANG Wuxiao.Microvascular Dysfunction in Patients with Acute ST-Segment?levation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2022,(3):530.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.013]
[10]纪欣强 王凡.肥胖悖论与经皮冠状动脉介入治疗预后相关性的研究进展[J].心血管病学进展,2022,(7):615.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
JI XinqiangWANG Fan.Correlation Between Obesity Paradox and Prognosis of Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(3):615.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]